	US 12,433,946 B2
	Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
Darrell J. Irvine, Arlington, MA (US); Karl Dane Wittrup, Boston, MA (US); Tyson Moyer, Boston, MA (US); and Yash Agarwal, Cambridge, MA (US)
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Feb. 22, 2023, as Appl. No. 18/172,905.
Application 18/172,905 is a continuation of application No. 16/857,999, filed on Apr. 24, 2020, granted, now 11,642,409.
Claims priority of provisional application 62/867,162, filed on Jun. 26, 2019.
Prior Publication US 2023/0302128 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 33/08 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 14/525 (2006.01); C07K 14/54 (2006.01); C07K 16/28 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 33/08 (2013.01); A61K 38/191 (2013.01); A61K 38/195 (2013.01); A61K 38/20 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 14/525 (2013.01); C07K 14/54 (2013.01); C07K 16/2809 (2013.01); C07K 2319/30 (2013.01)]

24 Claims

1. An immunomodulatory fusion protein comprising:

(a) an immunomodulatory domain, wherein the immunomodulatory domain is or comprises interleukin-12 (IL-12); and

(b) a metal hydroxide-binding peptide having an amino acid sequence motif comprising at least one phosphorylated amino acid, which sequence motif is or comprises: S-X-E, S-X-pS, or S-X-Q-X-X-D-E (SEQ ID NO: 206), wherein X is any amino acid.